Previous studies elucidated that MT1H was downregulated in colorectal cancer (Jansová et al., 2006), osteosarcoma (Endo-Munoz et al., 2010), and prostate cancer (Han et al., 2013) and conversely upregulated in soft tissue sarcoma (Skubitz et al., 2012) and non-small-cell lung cancer (Werynska et al., 2013). Here, MT1H is linked to prostate carcinoma.